You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAliskiren
Accession NumberDB09026  (DB01258)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAliskiren is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit. In December 2011, Novartis halted a clinical trial of the drug after discovering increased incidence of nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney impairment.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
Rasileztablet150 mgoralNovartis Pharmaceuticals Canada Inc2007-11-26Not applicableCanada
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
Rasileztablet300 mgoralNovartis Pharmaceuticals Canada Inc2007-11-29Not applicableCanada
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet300 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
RasilezFilm-coated tablet150 mgOral useNovartis Europharm Limited2007-08-22Not applicableEu
Sandoz Aliskirentablet300 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Aliskirentablet150 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Tekturnatablet, film coated150 mg/1oralNovartis Pharmaceuticals Corporation2007-03-05Not applicableUs
Tekturnatablet, film coated300 mg/1oralNovartis Pharmaceuticals Corporation2007-03-05Not applicableUs
Tekturnatablet, film coated150 mg/1oralPhysicians Total Care, Inc.2007-05-23Not applicableUs
Tekturnatablet, film coated300 mg/1oralPhysicians Total Care, Inc.2009-06-22Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
AmturnideNovartis Pharmaceuticals Corporation
Rasilez HctNovartis Pharmaceuticals Canada Inc
TekamloNovartis Pharmaceuticals Corporation
Tekturna HctNovartis Pharmaceuticals Corporation
Salts
Name/CASStructureProperties
Aliskiren hemifumarate
ThumbNot applicableDBSALT001203
Categories
UNII502FWN4Q32
CAS number173334-57-1
WeightAverage: 551.7583
Monoisotopic: 551.393436443
Chemical FormulaC30H53N3O6
InChI KeyUXOWGYHJODZGMF-QORCZRPOSA-N
InChI
InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
IUPAC Name
(2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide
SMILES
COCCCOC1=C(OC)C=CC(C[C@@H](C[[email protected]](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as delta amino acids and derivatives. These are compounds containing a carboxylic acid group and an amino group at the C5 carbon atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentDelta amino acids and derivatives
Alternative Parents
Substituents
  • Delta amino acid or derivatives
  • Phenylbutylamine
  • Beta amino acid or derivatives
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Ether
  • Dialkyl ether
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypertension, to lower blood pressure.
PharmacodynamicsIn placebo controlled clinical trials, plasma renin activity (PRA) was decreased in a range of 50% to 80%. This reduction in PRA was not dose‐related and did not correlate with blood pressure reductions. The clinical implications of the differences in effect on PRA are not known.
Mechanism of actionRenin is secreted by the kidney in response to decreases in blood volume and renal perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non‐ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system. This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin‐angiotensin‐aldosterone system (RAAS). Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non‐ACE pathways, is not known. All agents that inhibit the RAAS, including renin inhibitors, suppress the negative feedback loop, leading to a compensatory rise in plasma renin concentration. When this rise occurs during treatment with ACEIs and ARBs, the result is increased levels of PRA. During treatment with aliskiren, however, the effect of increased renin levels is blocked so that PRA, Ang I and Ang II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.
Related Articles
AbsorptionPoor, with a bioavailability of about 2.5%.
Volume of distributionNot Available
Protein binding47-51%
Metabolism

Approximately 80% of the drug in plasma following oral administration is unchanged. Cytochrome P450 (CYP) 3A4 oxidation produces two major metabolites that account for approximately 5% of the drug in plasma. Aliskiren is eliminated primarily through the biliary/fecal route as unchanged drug and, to a lesser extent, via oxidative metabolism via CYP3A4. Only 0.6% of the oral dose is recovered in urine.

Route of eliminationAbout one fourth of the absorbed dose appears in the urine as parent drug.
Half lifeApproximate accumulation half‐life of 24 hours.
ClearanceNot Available
ToxicityThe most likely manifestation of overdosage would be hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Film-coated tabletOral use150 mg
Film-coated tabletOral use300 mg
Tabletoral150 mg
Tabletoral300 mg
Tabletoral
Tablet, film coatedoral150 mg/1
Tablet, film coatedoral300 mg/1
Tablet, film coatedoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2147056 No2005-10-252015-04-13Canada
US5559111 No1998-07-212018-07-21Us
US8168616 No2006-07-032026-07-03Us
US8183295 No2003-05-162023-05-16Us
US8613949 No2009-12-212029-12-21Us
US8617595 No2006-02-192026-02-19Us
US8618172 No2008-07-132028-07-13Us
US8618174 No2001-11-152021-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityHighly soluble in water (as hemifumarate salt)Not Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0021 mg/mLALOGPS
logP3.87ALOGPS
logP3.12ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)14.56ChemAxon
pKa (Strongest Basic)9.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area146.13 Å2ChemAxon
Rotatable Bond Count19ChemAxon
Refractivity154.32 m3·mol-1ChemAxon
Polarizability64.25 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. [PubMed:18611061 ]
  2. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 Mar 1;111(8):1012-8. Epub 2005 Feb 21. [PubMed:15723979 ]
  3. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet. 2006 Oct 21;368(9545):1449-56. [PubMed:17055947 ]
External Links
ATC CodesC09DX02C09XA52C09XA02C09XA54C09XA53
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (612 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Aliskiren.
AcebutololAcebutolol may increase the hypotensive activities of Aliskiren.
AceclofenacAceclofenac may decrease the antihypertensive activities of Aliskiren.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Aliskiren.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Aliskiren.
AdapaleneAdapalene may decrease the antihypertensive activities of Aliskiren.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.
AlfuzosinAlfuzosin may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Aliskiren.
AmbrisentanAliskiren may increase the hypotensive activities of Ambrisentan.
AmifostineAliskiren may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Aliskiren.
AmiodaroneThe metabolism of Aliskiren can be decreased when combined with Amiodarone.
AmlodipineAmlodipine may increase the hypotensive activities of Aliskiren.
AmobarbitalAmobarbital may increase the hypotensive activities of Aliskiren.
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Aliskiren.
AntipyrineAntipyrine may decrease the antihypertensive activities of Aliskiren.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Aliskiren.
ApremilastApremilast may decrease the antihypertensive activities of Aliskiren.
AprepitantThe serum concentration of Aliskiren can be increased when it is combined with Aprepitant.
ArdeparinArdeparin may increase the hyperkalemic activities of Aliskiren.
AripiprazoleAripiprazole may increase the hypotensive activities of Aliskiren.
AtazanavirThe metabolism of Aliskiren can be decreased when combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Aliskiren.
AtomoxetineThe metabolism of Aliskiren can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Aliskiren can be increased when it is combined with Atorvastatin.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Aliskiren.
AzelastineAzelastine may decrease the antihypertensive activities of Aliskiren.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Aliskiren.
BalsalazideBalsalazide may decrease the antihypertensive activities of Aliskiren.
BarbitalBarbital may increase the hypotensive activities of Aliskiren.
BemiparinBemiparin may increase the hyperkalemic activities of Aliskiren.
BenazeprilBenazepril may increase the hypotensive activities of Aliskiren.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Aliskiren.
BenmoxinBenmoxin may increase the hypotensive activities of Aliskiren.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Aliskiren.
BepridilBepridil may increase the hypotensive activities of Aliskiren.
BetaxololBetaxolol may increase the hypotensive activities of Aliskiren.
BethanidineBethanidine may increase the hypotensive activities of Aliskiren.
BexaroteneThe serum concentration of Aliskiren can be decreased when it is combined with Bexarotene.
BimatoprostBimatoprost may increase the hypotensive activities of Aliskiren.
BisoprololBisoprolol may increase the hypotensive activities of Aliskiren.
BoceprevirThe metabolism of Aliskiren can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Aliskiren can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Aliskiren can be decreased when it is combined with Bosentan.
BosentanAliskiren may increase the hypotensive activities of Bosentan.
BretyliumBretylium may increase the hypotensive activities of Aliskiren.
BrimonidineAliskiren may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Aliskiren.
BromfenacBromfenac may decrease the antihypertensive activities of Aliskiren.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aliskiren.
BupranololBupranolol may increase the hypotensive activities of Aliskiren.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Aliskiren.
CanagliflozinThe risk or severity of adverse effects can be increased when Aliskiren is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Aliskiren.
CandoxatrilCandoxatril may increase the hypotensive activities of Aliskiren.
CaptoprilCaptopril may increase the hypotensive activities of Aliskiren.
CarbamazepineThe metabolism of Aliskiren can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Aliskiren.
CarprofenCarprofen may decrease the antihypertensive activities of Aliskiren.
CarteololCarteolol may increase the hypotensive activities of Aliskiren.
CarvedilolCarvedilol may increase the hypotensive activities of Aliskiren.
CastanospermineCastanospermine may decrease the antihypertensive activities of Aliskiren.
CelecoxibCelecoxib may decrease the antihypertensive activities of Aliskiren.
CeliprololCeliprolol may increase the hypotensive activities of Aliskiren.
CeritinibThe serum concentration of Aliskiren can be increased when it is combined with Ceritinib.
CertoparinCertoparin may increase the hyperkalemic activities of Aliskiren.
ChloroquineChloroquine may decrease the antihypertensive activities of Aliskiren.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Aliskiren.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Aliskiren.
CilazaprilCilazapril may increase the hypotensive activities of Aliskiren.
ClarithromycinThe metabolism of Aliskiren can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Aliskiren can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.
ClonidineClonidine may increase the hypotensive activities of Aliskiren.
ClonixinClonixin may decrease the antihypertensive activities of Aliskiren.
ClotrimazoleThe metabolism of Aliskiren can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Aliskiren can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Aliskiren can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Aliskiren can be decreased when combined with Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Aliskiren.
CyclosporineThe serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Aliskiren.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Aliskiren.
DabrafenibThe serum concentration of Aliskiren can be decreased when it is combined with Dabrafenib.
DalteparinDalteparin may increase the hyperkalemic activities of Aliskiren.
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.
DarunavirThe metabolism of Aliskiren can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Aliskiren can be increased when it is combined with Dasatinib.
DebrisoquinDebrisoquin may increase the hypotensive activities of Aliskiren.
DeferasiroxThe serum concentration of Aliskiren can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Aliskiren can be decreased when combined with Delavirdine.
DeserpidineAliskiren may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Aliskiren can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aliskiren.
DiazoxideDiazoxide may increase the hypotensive activities of Aliskiren.
DiclofenacDiclofenac may decrease the antihypertensive activities of Aliskiren.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Aliskiren.
DiflunisalDiflunisal may decrease the antihypertensive activities of Aliskiren.
DihydroergotamineThe metabolism of Aliskiren can be decreased when combined with Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Aliskiren.
DinutuximabThe risk or severity of adverse effects can be increased when Aliskiren is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Aliskiren.
DorzolamideDorzolamide may increase the hypotensive activities of Aliskiren.
DoxazosinDoxazosin may increase the hypotensive activities of Aliskiren.
DoxycyclineThe metabolism of Aliskiren can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Aliskiren can be decreased when combined with Dronedarone.
DrospirenoneDrospirenone may increase the hyperkalemic activities of Aliskiren.
DroxicamDroxicam may decrease the antihypertensive activities of Aliskiren.
DuloxetineAliskiren may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe serum concentration of Aliskiren can be decreased when it is combined with Efavirenz.
EfonidipineAliskiren may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Aliskiren.
EnalaprilatAliskiren may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Aliskiren.
EnzalutamideThe serum concentration of Aliskiren can be decreased when it is combined with Enzalutamide.
EpirizoleEpirizole may decrease the antihypertensive activities of Aliskiren.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Aliskiren.
EpoprostenolEpoprostenol may increase the hypotensive activities of Aliskiren.
EprosartanEprosartan may increase the hypotensive activities of Aliskiren.
ErythromycinThe metabolism of Aliskiren can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Aliskiren can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Aliskiren.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aliskiren.
EtanerceptEtanercept may decrease the antihypertensive activities of Aliskiren.
EtodolacEtodolac may decrease the antihypertensive activities of Aliskiren.
EtofenamateEtofenamate may decrease the antihypertensive activities of Aliskiren.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Aliskiren.
EtravirineThe serum concentration of Aliskiren can be decreased when it is combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Aliskiren.
exisulindexisulind may decrease the antihypertensive activities of Aliskiren.
FelodipineFelodipine may increase the hypotensive activities of Aliskiren.
FenbufenFenbufen may decrease the antihypertensive activities of Aliskiren.
FenoldopamFenoldopam may increase the hypotensive activities of Aliskiren.
FenoprofenFenoprofen may decrease the antihypertensive activities of Aliskiren.
FloctafenineFloctafenine may decrease the antihypertensive activities of Aliskiren.
FluconazoleThe metabolism of Aliskiren can be decreased when combined with Fluconazole.
FlunixinFlunixin may decrease the antihypertensive activities of Aliskiren.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Aliskiren.
FluvoxamineThe metabolism of Aliskiren can be decreased when combined with Fluvoxamine.
ForasartanAliskiren may increase the hyperkalemic activities of Forasartan.
FosamprenavirThe metabolism of Aliskiren can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Aliskiren can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Aliskiren.
FosphenytoinThe metabolism of Aliskiren can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Aliskiren.
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Aliskiren.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Aliskiren.
Fusidic AcidThe serum concentration of Aliskiren can be increased when it is combined with Fusidic Acid.
GuanabenzGuanabenz may increase the hypotensive activities of Aliskiren.
GuanadrelGuanadrel may increase the hypotensive activities of Aliskiren.
GuanethidineGuanethidine may increase the hypotensive activities of Aliskiren.
GuanfacineGuanfacine may increase the hypotensive activities of Aliskiren.
HeparinHeparin may increase the hyperkalemic activities of Aliskiren.
HexamethoniumHexamethonium may increase the hypotensive activities of Aliskiren.
HexobarbitalHexobarbital may increase the hypotensive activities of Aliskiren.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Aliskiren.
HydracarbazineHydracarbazine may increase the hypotensive activities of Aliskiren.
HydralazineHydralazine may increase the hypotensive activities of Aliskiren.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Aliskiren.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Aliskiren.
IbuprofenIbuprofen may decrease the antihypertensive activities of Aliskiren.
IbuproxamIbuproxam may decrease the antihypertensive activities of Aliskiren.
IcatibantIcatibant may decrease the antihypertensive activities of Aliskiren.
IdelalisibThe serum concentration of Aliskiren can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Aliskiren.
ImatinibThe metabolism of Aliskiren can be decreased when combined with Imatinib.
IndapamideIndapamide may increase the hypotensive activities of Aliskiren.
IndenololIndenolol may increase the hypotensive activities of Aliskiren.
IndinavirThe metabolism of Aliskiren can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Aliskiren.
IndoprofenIndoprofen may decrease the antihypertensive activities of Aliskiren.
IndoraminIndoramin may increase the hypotensive activities of Aliskiren.
IproclozideIproclozide may increase the hypotensive activities of Aliskiren.
IproniazidIproniazid may increase the hypotensive activities of Aliskiren.
IrbesartanIrbesartan may increase the hypotensive activities of Aliskiren.
IsavuconazoniumThe metabolism of Aliskiren can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Aliskiren.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Aliskiren.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Aliskiren.
IsoxicamIsoxicam may decrease the antihypertensive activities of Aliskiren.
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Aliskiren.
IsradipineIsradipine may increase the hypotensive activities of Aliskiren.
ItraconazoleThe serum concentration of Aliskiren can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Aliskiren can be increased when it is combined with Ivacaftor.
KebuzoneKebuzone may decrease the antihypertensive activities of Aliskiren.
KetoconazoleThe serum concentration of Aliskiren can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Aliskiren.
KetorolacKetorolac may decrease the antihypertensive activities of Aliskiren.
LabetalolLabetalol may increase the hypotensive activities of Aliskiren.
LacidipineAliskiren may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Aliskiren.
LeflunomideLeflunomide may decrease the antihypertensive activities of Aliskiren.
LercanidipineLercanidipine may increase the hypotensive activities of Aliskiren.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Aliskiren.
LevodopaAliskiren may increase the orthostatic hypotensive activities of Levodopa.
LisinoprilLisinopril may increase the hypotensive activities of Aliskiren.
LofexidineLofexidine may increase the hypotensive activities of Aliskiren.
LopinavirThe metabolism of Aliskiren can be decreased when combined with Lopinavir.
LornoxicamLornoxicam may decrease the antihypertensive activities of Aliskiren.
LosartanLosartan may increase the hypotensive activities of Aliskiren.
LovastatinThe metabolism of Aliskiren can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Aliskiren.
LuliconazoleThe serum concentration of Aliskiren can be increased when it is combined with Luliconazole.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Aliskiren.
MacitentanAliskiren may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Aliskiren.
ManidipineAliskiren may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Aliskiren.
MasoprocolMasoprocol may decrease the antihypertensive activities of Aliskiren.
MebanazineMebanazine may increase the hypotensive activities of Aliskiren.
MecamylamineMecamylamine may increase the hypotensive activities of Aliskiren.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Aliskiren.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Aliskiren.
MeloxicamMeloxicam may decrease the antihypertensive activities of Aliskiren.
MesalazineMesalazine may decrease the antihypertensive activities of Aliskiren.
MetamizoleMetamizole may decrease the antihypertensive activities of Aliskiren.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Aliskiren.
MethohexitalMethohexital may increase the hypotensive activities of Aliskiren.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Aliskiren.
MethyldopaMethyldopa may increase the hypotensive activities of Aliskiren.
Methylene blueMethylene blue may increase the hypotensive activities of Aliskiren.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Aliskiren.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Aliskiren.
MetipranololMetipranolol may increase the hypotensive activities of Aliskiren.
MetolazoneMetolazone may increase the hypotensive activities of Aliskiren.
MetoprololMetoprolol may increase the hypotensive activities of Aliskiren.
MibefradilMibefradil may increase the hypotensive activities of Aliskiren.
MifepristoneThe metabolism of Aliskiren can be decreased when combined with Mifepristone.
MinaprineMinaprine may increase the hypotensive activities of Aliskiren.
MinoxidilMinoxidil may increase the hypotensive activities of Aliskiren.
MitotaneThe serum concentration of Aliskiren can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypotensive activities of Aliskiren.
ModafinilThe serum concentration of Aliskiren can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Aliskiren.
MolsidomineMolsidomine may increase the hypotensive activities of Aliskiren.
MoxonidineAliskiren may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Aliskiren.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Aliskiren.
NabumetoneNabumetone may decrease the antihypertensive activities of Aliskiren.
NadololNadolol may increase the hypotensive activities of Aliskiren.
NadroparinNadroparin may increase the hyperkalemic activities of Aliskiren.
NafcillinThe serum concentration of Aliskiren can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the antihypertensive activities of Aliskiren.
NaproxenNaproxen may decrease the antihypertensive activities of Aliskiren.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Aliskiren.
NebivololNebivolol may increase the hypotensive activities of Aliskiren.
NefazodoneThe metabolism of Aliskiren can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Aliskiren can be decreased when combined with Nelfinavir.
NepafenacNepafenac may decrease the antihypertensive activities of Aliskiren.
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Aliskiren.
NetupitantThe serum concentration of Aliskiren can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Aliskiren can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Aliskiren.
NicardipineNicardipine may increase the hypotensive activities of Aliskiren.
NicorandilNicorandil may increase the hypotensive activities of Aliskiren.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Aliskiren.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Aliskiren.
NiguldipineAliskiren may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Aliskiren can be decreased when combined with Nilotinib.
NilvadipineNilvadipine may increase the hypotensive activities of Aliskiren.
NimesulideNimesulide may decrease the antihypertensive activities of Aliskiren.
NimodipineNimodipine may increase the hypotensive activities of Aliskiren.
NisoldipineNisoldipine may increase the hypotensive activities of Aliskiren.
NitrendipineNitrendipine may increase the hypotensive activities of Aliskiren.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Aliskiren.
NitroprussideNitroprusside may increase the hypotensive activities of Aliskiren.
ObinutuzumabAliskiren may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Aliskiren.
OlaparibThe metabolism of Aliskiren can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Aliskiren.
OlopatadineOlopatadine may decrease the antihypertensive activities of Aliskiren.
OlsalazineOlsalazine may decrease the antihypertensive activities of Aliskiren.
OmapatrilatOmapatrilat may increase the hypotensive activities of Aliskiren.
OrgoteinOrgotein may decrease the antihypertensive activities of Aliskiren.
OsimertinibThe serum concentration of Aliskiren can be increased when it is combined with Osimertinib.
OxaprozinOxaprozin may decrease the antihypertensive activities of Aliskiren.
OxprenololOxprenolol may increase the hypotensive activities of Aliskiren.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Aliskiren.
PalbociclibThe serum concentration of Aliskiren can be increased when it is combined with Palbociclib.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Aliskiren.
ParecoxibParecoxib may decrease the antihypertensive activities of Aliskiren.
PargylinePargyline may increase the hypotensive activities of Aliskiren.
ParnaparinParnaparin may increase the hyperkalemic activities of Aliskiren.
PenbutololPenbutolol may increase the hypotensive activities of Aliskiren.
PentobarbitalPentobarbital may increase the hypotensive activities of Aliskiren.
PentoliniumPentolinium may increase the hypotensive activities of Aliskiren.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Aliskiren.
PerindoprilPerindopril may increase the hypotensive activities of Aliskiren.
PhenelzinePhenelzine may increase the hypotensive activities of Aliskiren.
PheniprazinePheniprazine may increase the hypotensive activities of Aliskiren.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Aliskiren.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Aliskiren.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Aliskiren.
PhentolaminePhentolamine may increase the hypotensive activities of Aliskiren.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Aliskiren.
PhenytoinThe metabolism of Aliskiren can be increased when combined with Phenytoin.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Aliskiren.
PinacidilPinacidil may increase the hypotensive activities of Aliskiren.
PindololPindolol may increase the hypotensive activities of Aliskiren.
PirfenidonePirfenidone may decrease the antihypertensive activities of Aliskiren.
PirlindolePirlindole may increase the hypotensive activities of Aliskiren.
PiroxicamPiroxicam may decrease the antihypertensive activities of Aliskiren.
PivhydrazinePivhydrazine may increase the hypotensive activities of Aliskiren.
PolythiazidePolythiazide may increase the hypotensive activities of Aliskiren.
PosaconazoleThe metabolism of Aliskiren can be decreased when combined with Posaconazole.
PrazosinPrazosin may increase the hypotensive activities of Aliskiren.
PrimidonePrimidone may increase the hypotensive activities of Aliskiren.
PropacetamolPropacetamol may decrease the antihypertensive activities of Aliskiren.
PropranololPropranolol may increase the hypotensive activities of Aliskiren.
PTC299PTC299 may decrease the antihypertensive activities of Aliskiren.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aliskiren.
QuinaprilQuinapril may increase the hypotensive activities of Aliskiren.
QuinineQuinine may increase the hypotensive activities of Aliskiren.
RamiprilRamipril may increase the hypotensive activities of Aliskiren.
RanolazineThe metabolism of Aliskiren can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Aliskiren.
RemikirenRemikiren may increase the hypotensive activities of Aliskiren.
RescinnamineAliskiren may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Aliskiren.
ResveratrolResveratrol may decrease the antihypertensive activities of Aliskiren.
ReviparinReviparin may increase the hyperkalemic activities of Aliskiren.
RifabutinThe metabolism of Aliskiren can be increased when combined with Rifabutin.
RifampicinThe metabolism of Aliskiren can be increased when combined with Rifampicin.
RifapentineThe metabolism of Aliskiren can be increased when combined with Rifapentine.
RiociguatAliskiren may increase the hypotensive activities of Riociguat.
RisperidoneAliskiren may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Aliskiren can be decreased when combined with Ritonavir.
RituximabAliskiren may increase the hypotensive activities of Rituximab.
RofecoxibRofecoxib may decrease the antihypertensive activities of Aliskiren.
SafrazineSafrazine may increase the hypotensive activities of Aliskiren.
SalicylamideSalicylamide may decrease the antihypertensive activities of Aliskiren.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Aliskiren.
SalsalateSalsalate may decrease the antihypertensive activities of Aliskiren.
SaprisartanSaprisartan may increase the hypotensive activities of Aliskiren.
SaquinavirThe metabolism of Aliskiren can be decreased when combined with Saquinavir.
SaralasinAliskiren may increase the hyperkalemic activities of Saralasin.
SecobarbitalSecobarbital may increase the hypotensive activities of Aliskiren.
SelegilineSelegiline may increase the hypotensive activities of Aliskiren.
SelexipagAliskiren may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Aliskiren.
SildenafilSildenafil may increase the antihypertensive activities of Aliskiren.
SiltuximabThe serum concentration of Aliskiren can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Aliskiren can be increased when it is combined with Simeprevir.
SitaxentanAliskiren may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Aliskiren.
SpiraprilSpirapril may increase the hypotensive activities of Aliskiren.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Aliskiren.
SRT501SRT501 may decrease the antihypertensive activities of Aliskiren.
St. John's WortThe serum concentration of Aliskiren can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Aliskiren can be increased when it is combined with Stiripentol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Aliskiren.
SulfisoxazoleThe metabolism of Aliskiren can be decreased when combined with Sulfisoxazole.
SulindacSulindac may decrease the antihypertensive activities of Aliskiren.
SuprofenSuprofen may decrease the antihypertensive activities of Aliskiren.
TadalafilTadalafil may increase the antihypertensive activities of Aliskiren.
TasosartanAliskiren may increase the hyperkalemic activities of Tasosartan.
TelaprevirThe metabolism of Aliskiren can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Aliskiren can be decreased when combined with Telithromycin.
TelmisartanTelmisartan may increase the hypotensive activities of Aliskiren.
TemocaprilTemocapril may increase the hypotensive activities of Aliskiren.
TenoxicamTenoxicam may decrease the antihypertensive activities of Aliskiren.
TepoxalinTepoxalin may decrease the antihypertensive activities of Aliskiren.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Aliskiren.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Aliskiren.
TerlipressinTerlipressin may increase the hypotensive activities of Aliskiren.
ThiamylalThiamylal may increase the hypotensive activities of Aliskiren.
ThiopentalThiopental may increase the hypotensive activities of Aliskiren.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Aliskiren.
TiboloneAliskiren may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Aliskiren can be decreased when combined with Ticlopidine.
TicrynafenTicrynafen may increase the hypotensive activities of Aliskiren.
TimololTimolol may increase the hypotensive activities of Aliskiren.
TinzaparinTinzaparin may increase the hyperkalemic activities of Aliskiren.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aliskiren.
TocilizumabThe serum concentration of Aliskiren can be decreased when it is combined with Tocilizumab.
TolazolineTolazoline may increase the hypotensive activities of Aliskiren.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Aliskiren.
TolmetinTolmetin may decrease the antihypertensive activities of Aliskiren.
ToloxatoneToloxatone may increase the hypotensive activities of Aliskiren.
TorasemideTorasemide may increase the hypotensive activities of Aliskiren.
TrandolaprilTrandolapril may increase the hypotensive activities of Aliskiren.
TranilastTranilast may decrease the antihypertensive activities of Aliskiren.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Aliskiren.
TranylcypromineTranylcypromine may increase the hypotensive activities of Aliskiren.
TravoprostTravoprost may increase the hypotensive activities of Aliskiren.
TreprostinilTreprostinil may increase the hypotensive activities of Aliskiren.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Aliskiren.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Aliskiren.
TrimazosinAliskiren may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Aliskiren.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Aliskiren.
UdenafilUdenafil may increase the antihypertensive activities of Aliskiren.
UnoprostoneUnoprostone may increase the hypotensive activities of Aliskiren.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Aliskiren.
ValsartanValsartan may increase the hypotensive activities of Aliskiren.
VardenafilVardenafil may increase the antihypertensive activities of Aliskiren.
VenlafaxineThe metabolism of Aliskiren can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Aliskiren can be increased when it is combined with Verapamil.
VerapamilThe risk or severity of adverse effects can be increased when Aliskiren is combined with Verapamil.
VoriconazoleThe metabolism of Aliskiren can be decreased when combined with Voriconazole.
XylometazolineXylometazoline may increase the hypotensive activities of Aliskiren.
YohimbineYohimbine may decrease the antihypertensive activities of Aliskiren.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Aliskiren.
ZileutonZileuton may decrease the antihypertensive activities of Aliskiren.
ZiprasidoneThe metabolism of Aliskiren can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may decrease the antihypertensive activities of Aliskiren.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney.
Gene Name:
REN
Uniprot ID:
P00797
Molecular Weight:
45057.125 Da
References
  1. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 Jan;39(1):E1-8. [PubMed:11799102 ]
  2. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705. [PubMed:12927775 ]
  3. Menard J, Guyene TT, Peyrard S, Azizi M: Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens. 2006 Mar;24(3):529-34. [PubMed:16467656 ]
  4. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006 Feb;24(2):243-56. [PubMed:16508564 ]
  5. Gradman AH, Vivas Y: New drugs for hypertension: what do they offer? Curr Hypertens Rep. 2006 Oct;8(5):425-32. [PubMed:16965731 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. [PubMed:18611061 ]
Comments
comments powered by Disqus
Drug created on October 13, 2014 16:29 / Updated on September 27, 2016 02:27